
HERO provides access to companies whose principal business have or are expected have significant exposure to the field of video games and esports. An algorithm screens company filings for keywords that match the index theme to identify and rank companies. Eligible securities meeting minimum market-cap and liquidity requirements must also generate at least 50% of its revenues from video games or esports activities to be selected for index inclusion. Securities are those in the emerging and developed countries. The fund also invests in ADRs and GDRs based on such securities, and is not limited…
Is HERO's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

Duke Energy supports South Carolina first responders with $500,000 in grants for emergency preparedness PR Newswire

Funding goes to 34 nonprofits and government agencies across the Palmetto State Since 2022, Duke Energy's HERO Grant Program has funded 133 grants with $2.5 million, delivering critical support to nonprofits and local agencies GREENVILLE, S.C., June 5, 2026 /PRNewswire/ -- As emergency managers, first responders and community leaders are preparing their communities for the 2026 hurricane season, the Duke Energy Foundation is awarding $500,000 through the 2026 Helping Emergency Response Organizations (HERO) Grant Program to help South Carolina communities be prepared for the impacts from severe weather.

SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company's previously announced voluntary pause. The clinical hold applies to all ongoing clinical studies under the IND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS) and the Phase 3 open-label extension (OLE) trial (AVK-101-302). The Company remains in active discussions with the FDA to support resolution of the clinical hold and determine a path forward for the ARD-101 program.

Digital entertainment has grown into one of the largest discretionary categories for consumers, and it continues to draw more time and attention every year.

AI in the video gaming industry could cut development costs by 50%, unlocking $22B in profits, lifting ETF plays like ESPO and HERO.